Sozial- und Präventivmedizin

, Volume 36, Issue 6, pp 333–340

Fréquence d'utilisation des différents traitements de l'infarctus du myocarde dans deux régions suisses

  • Jean-Marie Gothuey
  • Vincent Wietlisbach
  • Martin Rickenbach
  • Fabrizio Barazzoni
  • Carlo la Vecchia
Article

Résumé

Deux régions suisses (Vaud-Fribourg et Tessin) participent au projet international MONICA patronné par l'OMS (MONItoring of trends and determinants in CArdiovascular disease). Dans ce cadre, toutes les hospitalisations des hommes pour maladie ischémique du coeur, sont enregistrées pendant une période de 10 ans. Les cas sont classés selon des critères uniformes en trois catégories: infarctus certain, infarctus possible ou pas d'infarctus. En 1986, l'étude a été complétée par un relevé des traitements. Dans cet article, l'analyse principale des soins se limite aux patients âgés de 25 à 64 ans survivant à 27 jours et porte sur 334 cas avec un infarctus certain (VD-FR: 217; TI: 117). Les résultats montrent que les anticoagulants étaient administrés de manière routinière (97% des cas) alors que la thrombolyse, pratiquée en 1986 par un seul hôpital dans chaque région, ne touchait que 9% des patients. La région romande se distinguait du Tessin par un usage significativement plus fréquent d'antiarythmiques (69% contre 47%; p<0.005), de dérivés nitrés (97% contre 86%; p<0.005) et de bêta-bloquants (57% contre 43%; p<0.05). En plus, les patients romands séjournaient plus longtemps aux soins intensifs (6.4 contre 3.7 jours; p<0.005) et bénéficiaient plus fréquemment d'un programme de réhabilitation (47% contre 12%; p<0.005). La discussion situe la pratique thérapeutique par rapport aux résultats publiés dans la littérature.

Summary

Two regions in Switzerland (Vaud-Fribourg and Ticino) participate in the WHO MONICA project (MONItoring of trends and determinants in CArdiovascular disease). Within this context, all hospitalizations of men for ischemic heart disease will be recorded during a period of ten years. All cases are classified according to uniform criteria, in three categories: definite myocardial infarction, possible myocardial infarction or no myocardial infarction. In 1986, the records were completed with a summary of treatments. The treatment of 334 patients with definite myocardial infarction, aged between 25 and 64 years, surviving after 27 days are analyzed (VD-FR: 217; TI: 117). Results show that anticoagulants were administred in a routine fashion (in 97% of the cases), whilst thrombolysis, applied in 1986 by only one hospital in each area, concerned only 9% of the patients. As compared to Ticino, VD-FR distinguished itself by its significantly higher use of antiarythmic drugs (69% versus 47%; p<0.005), nitrates (97% versus 86%; p<0.005) and beta-blockers (57% versus 43%; p<0.05). Furthermore, patients from VD-FR spent more time in the intensive care unit (6.4 versus 3.7 days; p<0.005) and participated more frequently in rehabilitation programmes (47% versus 12%; p<0.005). The discussion situates the observed therapy in relation to results published in the litcrature.

Zusammenfassung

Die Schweiz beteiligt sich mit zwei Gebieten (Waadt-Freiburg und Tessin) am Monica-Projekt der Weltgesundheitsorganisation (MONItoring of trends and determinants in CArdiovascular disease). In diesem Zusammenhang werden alle Hospitalisationen von Männern, die an einer ischämischen Herzkrankheit leiden, über einen Zeitraum von 10 Jahren registriert. Die registrierten Fälle werden nach einheitlichen Kriterien klassiert als eindeutiger Fall von Herzinfarkt, möglicher Herzinfarkt oder als „kein Infarkt”. Für das Jahr 1986 wurde die Studie mit einer Erhebung der Therapiemassnahmen ergänzt. Es werden für die 25-64jährigen Patienten mit eindeutigem Herzinfarkt die Therapien in den beiden Studienregionen analysiert. Es sind dies 334 Hospitalisationen (VD-FR: 217; TI: 117). Die Resultate zeigen, dass der Einsatz von Antikoagulantien allgemein üblich war (97% der Infarkte), während die Thrombolyse, deren Anwendung in beiden Studiengebieten auf ein Spital beschränkt war, nur 9% der Patienten betraf. Für die französischsprachige Region stellt man eine im Vergleich zum Tessin signifikant häufigere Anwendung von Antiarythmika (69% gegen 47%; p<0,005), Nitraten (97% gegen 86%; p<0,005) und Beta-Blockern (57% gegen 43%; p<0,05) fest. Die Patienten im Welschland bleiben zudem länger auf der Intensivpflegestation (6,4 gegen 3,7 Tage; p<0,005) und mehr von ihnen profitieren von einem Rehabilitationsprogramm (47% gegen 12%; p<0,005). In der Diskussion wird die angewendete Therapie mit den Resultaten klinischer Studien verglichen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Bibliographiques

  1. 1.
    Uemura K, Pisa Z. Trends in cardiovascular disease mortality in industrialized countries since 1950. World Health Stat Q 1988;41: 155–79.PubMedGoogle Scholar
  2. 2.
    Thom TJ, Epstein FH, Feldman JJ, Leaverton PE. Trends in total mortality and mortality from heart disease in 26 countries from 1950 to 1978. Int J Epidemiol 1985;42: 510–20.Google Scholar
  3. 3.
    Wietlisbach V, Gutzwiller F. Mortalité cardio-vasculaire en Suisse: évolution de 1970 à 1980. Med Hyg 1984;42: 430–4.Google Scholar
  4. 4.
    La Vecchia C, Levi F, Negri E et al. Trands in mortality from coronary heart and cerebrovascular disease in Switzerland. Soz Praeventivmed 1991;36: 18–24.Google Scholar
  5. 5.
    WHO MONICA Project Principal Investigators. The World Health Organization MONICA Project (MONItoring trends and determinants in CArdiovascular disease): a major international collaboration. J Clin Epidemiol 1988;41: 105–14.Google Scholar
  6. 6.
    WHO MONICA Project/Böthig S. WHO MONICA Project: Objectives and Design. Int J Epidemiol 1989;18 (Suppl. 1): 29–37.Google Scholar
  7. 7.
    Prineas RRJ, Grow RS, Blackburn H. The Minnesota Code Manual of Electrocardiographic Findings: standards and procedures for measurement and classification. Boston: J. Wright, 1982.Google Scholar
  8. 8.
    Rickenbach M, Gutzwiller F, Wietlisbach V, Martin J, Epstein FH. Switzerland's participation in MONICA. Soz Praeventivmed 1985;30: 95–9.Google Scholar
  9. 9.
    Annuaire médical suisse 1988. Bâle: Schwabe, 1988.Google Scholar
  10. 10.
    Martin CA, Hobbs MST, Armstrong BK. Measuring the incidence of acute myocardial infarction: the problem of possible acute myocardial infarction. Acta Med Scand 1988; (Suppl. 728); 40–7.Google Scholar
  11. 11.
    Arveiler D, Cambou JP, Nuttens MC et al. Acute coronary care and treatment of myocardial infarction in the three French MONICA registers. Rev Epidém et Santé Publ 1990;38: 411–7.Google Scholar
  12. 12.
    Jaffe AS. Acute myocardial infarction: state of the art. Circulation 1986;74 (suppl. IV): 120–2.Google Scholar
  13. 13.
    Dalen JE, Goldberg RJ, Gore JM, Struckus J. Therapeutic interventions in acute myocardial infarction: survey of the ACCP section on clinical cardiology. Chest 1984;86: 257–62.PubMedGoogle Scholar
  14. 14.
    Pitt B. Therapy for myocardial infarction: effect on trends in coronary disease mortality. Int J Epidemiol 1989;18 (suppl. 1): 223–7.Google Scholar
  15. 15.
    MacMahon S, Collins R, Peto R, Koster RW, Yusuf S. Effects of prophylactic lidocaine in suspecte acute myocardial infarction: an overview of results from the randomized, controlled trials. JAMA 1988;260: 1910–6.PubMedGoogle Scholar
  16. 16.
    Pasternak RC, Braunwald E, Alpert JS. Acute myocardial infarction. In: E Braunwald, KJ Isselbacher, RG Pertersdorf, JD Wilson, JB Martin, SF Anthony, eds. Harrison's Principles of Internal Medicine. 11tth ed. New-York: McGraw-Hill, 1987: 982–92.Google Scholar
  17. 17.
    Hlatky MA, Cotugno HE, Mark DB, O'Connor C, Califf RM, Pryor DB. Trends in physician management of uncomplicated acute myocardial infarction, 1970 to 1987. Am J Cardiol 1988;61: 515–8.PubMedGoogle Scholar
  18. 18.
    Strano A, Davi G, Di Giorgi S. Role of anticoagulation and anti-aggregation. Eur Heart J 1986;7 (suppl C): 93–8.PubMedGoogle Scholar
  19. 19.
    Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. 1: treatments following myocardial infarction. JAMA 1988;260: 2088–93.PubMedGoogle Scholar
  20. 20.
    Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-2, a factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12490 patients with acute myocardial infarction. Lancet 1990;336: 65–71.Google Scholar
  21. 21.
    The International Study Group. In-hospital mortality and clinical course of 20891 patients with suspected acute myocardial infarction randomized between alteplase and streptokinase with or without heparin. Lancet 1990;336: 71–5.Google Scholar
  22. 22.
    Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 1988;296: 320–31.Google Scholar
  23. 23.
    Fuster V, Cohen M, Halperin J. Aspirin in the prevention of coronary disease. N Engl J Med 1989;321: 183–5.PubMedGoogle Scholar
  24. 24.
    Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog cardiovasc Dis 1985;27: 335–71.PubMedGoogle Scholar
  25. 25.
    ISIS-1 (First International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction, ISIS-1. Lancet 1986;2: 57–66.Google Scholar
  26. 26.
    The MIAMI Trial Research Group. Metoprolol in acute myocardial infarction (MIAMI): a randomized placebocontrolled international trial. Eur Heart J 1985;6: 199–226.Google Scholar
  27. 27.
    Frishman WH, Lazar EJ. Calcium channel blockers in patients with both hypertension and angina pectoris. J Cardiovasc Pharm 1988;12 (suppl 6): 69–74.Google Scholar
  28. 28.
    Schmoeckel M, Arendt RM, Hauck R, Schultheiss HP. Acute and chronic effects of Nitrendipine on hemodynamics and myocardial ischemia in patients with combined angina pectoris and hypertension. J Cardiovasc Pharm 1988;12 (suppl 4): 170–4.Google Scholar
  29. 29.
    Kiowski W. Die Behandlung der Ischämie beim akuten Myokardinfarkt. Schweiz med Wochenschr. 1990;120: 1531–8.PubMedGoogle Scholar
  30. 30.
    Jaillon P. Traitement de l'angine de poitrine: perspectives nouvelles. Presse med 1986;15: 1747–53.PubMedGoogle Scholar
  31. 31.
    Yusuf S, Collins R, MacMahon S, Peto R. Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomized trials. Lancet 1988;1: 1088–92.PubMedGoogle Scholar
  32. 32.
    ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2: 349–60.Google Scholar
  33. 33.
    Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1: 397–402.Google Scholar
  34. 34.
    The ISAM Study Group. A prospective trial of intravenous streptokinase in acute myocardial infarction (ISAM): mortality, morbidity, and infarct size at 21 days. N Engl J Med 1986;314: 1665–71.Google Scholar
  35. 35.
    Moret P, Chantraine A. Réadaptation des coronariens. Ther Umsch 1988;45: 458–65.PubMedGoogle Scholar
  36. 36.
    O'Connor GT, Buring JE, Yusuf S et al. An overview of randomized trials of rehabilitation with exercise after myocardial infarction. Circulation 1989;80: 234–44.PubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag 1991

Authors and Affiliations

  • Jean-Marie Gothuey
    • 1
  • Vincent Wietlisbach
    • 1
  • Martin Rickenbach
    • 1
  • Fabrizio Barazzoni
    • 2
  • Carlo la Vecchia
    • 1
  1. 1.Institut universitaire de médecine sociale et préventiveSwitzerland
  2. 2.Ufficio Medico CantonaleBellinzona

Personalised recommendations